In a groundbreaking study published in Molecular Therapy, an international team of researchers led by Professor Miguel Chillón from the Institute of Neurosciences at the Autonomous University of Barcelona (INc-UAB) has demonstrated that increasing levels of a specific protein, known as secreted Klotho Protein (s-KL), can significantly slow down the aging process. The treatment, tested in mice, not only extended their lifespan by 15–20% but also improved key health indicators such as muscle strength, bone density, and cognitive performance.
The study involved genetically modifying young mice to overproduce the s-KL protein using gene therapy. These treated mice were then monitored as they aged. At 24 months old—comparable to about 70 years in human age—the treated group displayed enhanced physical endurance, larger and healthier muscle fibers, and reduced muscle fibrosis. Female mice in particular also showed stronger bones and better preservation of internal bone structures, indicating protection against osteoporosis.
Klotho Protein Cognitive Benefits and Molecular Therapy, Mechanism
Beyond physical improvements, s-Klotho Protein treatment also had a positive effect on the brain. The research team observed increased neuron generation and enhanced immune activity in the hippocampus, a critical region for memory and learning. This suggests that s-KL could help preserve cognitive function and reduce the impact of age-related neurological decline.
The technique used to deliver the treatment involved a viral vector, specifically an adeno-associated virus (AAV9), which introduced the gene responsible for producing s-KL directly into the mice’s cells. In some cases, the vector was also administered directly into the brain to ensure sufficient protein expression within neural tissue. According to first author Joan Roig-Soriano, the development of viral vectors that can cross the blood-brain barrier makes future human application more feasible. Alternatively, scientists are also exploring ways to deliver the protein as a drug, although challenges remain in ensuring targeted delivery and stability.
Implications for Human Aging and Future Molecular Therapy,
This study marks a significant step forward in understanding how to slow down aging and promote healthier living in later years. While the findings are currently limited to animal models, the researchers are optimistic about the therapeutic potential of s-Klotho Protein in humans. Their earlier research had already led to patents related to treating cognitive decline, and the latest results have prompted three additional patents covering muscle and bone therapy, as well as longevity enhancement.
Klotho Protein has emerged as a promising candidate in anti-aging research due to its ability to regulate key biological processes, including insulin signaling and inflammation reduction. As the global population ages, therapies targeting multiple aspects of aging could drastically improve quality of life and reduce the burden of age-related diseases. “If we can find a viable delivery method, s-KL could make a significant contribution to improving people’s quality of life and helping to build the healthiest society possible,” the team concluded.
